Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial
Protein signatures dominated by acute-phase proteins define progression to RA, whereas changes associated with abatacept therapy highlight potential mechanisms of treatment response. Such signatures provide a better understanding of the immune landscape of the at-risk phase, opening up the possibility of new treatment modalities for RA prevention.
Authors
- Carl Coyle
- Marianna Jasenecova (ORCID: https://orcid.org/0000-0003-3080-8396)
- Esperanza Perucha (ORCID: https://orcid.org/0000-0002-7802-0875)
- Sarah Ryan (ORCID: https://orcid.org/0000-0002-0650-3069)
- Alina Mihalovits
- Andrew P Cope
- Sam Norton
- Melody Chin
- Elizabeth Pook
Institutions
- King's College London (GB)
- Institute for Rheumatic Diseases (Japan) (JP)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1002/art.70082
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- King's College London